Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2024)

Avalo Therapeutics filings provide 3 years of Preferred Stock Liabilities readings, the most recent being $1.7 million for Q3 2024.

On a quarterly basis, Preferred Stock Liabilities changed N/A to $1.7 million in Q3 2024 year-over-year; TTM through Sep 2024 was $1.7 million, a N/A change, with the full-year FY2014 number at $28.3 million, up 42.75% from a year prior.
Preferred Stock Liabilities hit $1.7 million in Q3 2024 for Avalo Therapeutics, down from $11.5 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $11.5 million in Q1 2024 to a low of $1.7 million in Q3 2024.